China SXT Pharmaceuticals, Inc. (SXTC)
USD 2.28
(2.7%)
USD 2.28
(2.7%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 | 1.92 Million USD | -2.19% |
| 2023 | 1.97 Million USD | -24.23% |
| 2022 | 2.6 Million USD | -45.53% |
| 2021 | 4.77 Million USD | -7.45% |
| 2020 | 5.16 Million USD | -26.38% |
| 2019 | 7.01 Million USD | -0.1% |
| 2018 | 7.01 Million USD | 43.79% |
| 2017 | 4.88 Million USD | 31.27% |
| 2016 | 3.71 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 494.45 Thousand USD | -47.37% |
| 2024 Q1 | 469.79 Thousand USD | -38.46% |
| 2024 Q4 | 494.45 Thousand USD | 0.0% |
| 2024 FY | 1.92 Million USD | -2.19% |
| 2024 Q2 | 939.58 Thousand USD | 100.0% |
| 2023 Q2 | 1.2 Million USD | 100.0% |
| 2023 Q4 | 763.39 Thousand USD | 100.0% |
| 2023 Q3 | 381.69 Thousand USD | -68.41% |
| 2023 Q1 | 604.14 Thousand USD | 105.25% |
| 2023 FY | 1.97 Million USD | -24.23% |
| 2022 Q1 | 513.83 Thousand USD | 105.51% |
| 2022 Q4 | -11.5 Million USD | -1560.97% |
| 2022 Q2 | 1.02 Million USD | 100.0% |
| 2022 Q3 | 787.3 Thousand USD | -23.39% |
| 2022 FY | 2.6 Million USD | -45.53% |
| 2021 Q3 | 458.53 Thousand USD | -76.24% |
| 2021 Q4 | -9.32 Million USD | -2134.08% |
| 2021 FY | 4.77 Million USD | -7.45% |
| 2021 Q2 | 1.93 Million USD | 0.0% |
| 2021 Q1 | 1.93 Million USD | -62.61% |
| 2020 Q2 | 3.21 Million USD | 100.0% |
| 2020 Q3 | 973.56 Thousand USD | -69.72% |
| 2020 FY | 5.16 Million USD | -26.38% |
| 2020 Q1 | 1.6 Million USD | -77.07% |
| 2020 Q4 | 5.16 Million USD | 430.25% |
| 2019 Q1 | 1.95 Million USD | 36.72% |
| 2019 FY | 7.01 Million USD | -0.1% |
| 2019 Q3 | 1.54 Million USD | -60.51% |
| 2019 Q2 | 3.91 Million USD | 100.0% |
| 2019 Q4 | 7.01 Million USD | 353.22% |
| 2018 FY | 7.01 Million USD | 43.79% |
| 2018 Q3 | 5.58 Million USD | 187.24% |
| 2018 Q4 | 1.43 Million USD | -74.35% |
| 2018 Q1 | 1.94 Million USD | 68.88% |
| 2018 Q2 | 1.94 Million USD | -0.0% |
| 2017 Q4 | 1.15 Million USD | 0.0% |
| 2017 FY | 4.88 Million USD | 31.27% |
| 2016 FY | 3.71 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ANI Pharmaceuticals, Inc. | 486.81 Million USD | 99.604% |
| Aquestive Therapeutics, Inc. | 50.58 Million USD | 96.187% |
| Collegium Pharmaceutical, Inc. | 566.76 Million USD | 99.66% |
| Cosmos Health Inc. | 53.37 Million USD | 96.387% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -79.161% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | 98.342% |
| Cronos Group Inc. | 88.84 Million USD | 97.829% |
| Incannex Healthcare Limited | 12 Thousand USD | -15970.808% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Lifecore Biomedical, Inc. | 128.26 Million USD | 98.496% |
| Regencell Bioscience Holdings Limited | - USD | -Infinity% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 91.996% |
| Sunshine Biopharma, Inc. | 24.09 Million USD | 91.996% |
| SCYNEXIS, Inc. | 140.14 Million USD | 98.624% |
| Safety Shot Inc | 202.67 Thousand USD | -851.545% |
| Theratechnologies Inc. | 81.76 Million USD | 97.641% |
| Alpha Teknova, Inc. | 36.68 Million USD | 94.743% |
| Universe Pharmaceuticals INC | 32.3 Million USD | 94.031% |
| Pacira BioSciences, Inc. | 674.97 Million USD | 99.714% |
| Sonoma Pharmaceuticals, Inc. | 12.73 Million USD | 84.857% |
| Dynavax Technologies Corporation | 232.28 Million USD | 99.17% |
| Ironwood Pharmaceuticals, Inc. | 442.73 Million USD | 99.564% |
| Radius Health, Inc. | 2.88 Billion USD | 99.933% |
| Alvotech | 91.43 Million USD | 97.891% |
| Intra-Cellular Therapies, Inc. | 464.37 Million USD | 99.585% |
| SIGA Technologies, Inc. | 139.91 Million USD | 98.622% |
| Shineco, Inc. | 9.8 Million USD | 80.325% |
| Silver Spike Investment Corp. | 11.72 Million USD | 83.548% |
| Journey Medical Corporation | 79.18 Million USD | 97.564% |
| Petros Pharmaceuticals, Inc. | 5.82 Million USD | 66.878% |
| Embecta Corp. | 1.12 Billion USD | 99.828% |
| Harrow Health, Inc. | 130.19 Million USD | 98.519% |
| Procaps Group, S.A. | 409.92 Million USD | 99.53% |
| Biofrontera Inc. | 34.07 Million USD | 94.34% |
| DURECT Corporation | 8.54 Million USD | 77.439% |
| PainReform Ltd. | - USD | -Infinity% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | 99.683% |
| OptiNose, Inc. | 70.98 Million USD | 97.283% |
| RedHill Biopharma Ltd. | 6.51 Million USD | 70.391% |
| Organogenesis Holdings Inc. | 433.14 Million USD | 99.555% |
| Cumberland Pharmaceuticals Inc. | 39.55 Million USD | 95.124% |
| ProPhase Labs, Inc. | 44.38 Million USD | 95.655% |
| Phibro Animal Health Corporation | 1.01 Billion USD | 99.811% |
| Procaps Group S.A. | 409.92 Million USD | 99.53% |
| TherapeuticsMD, Inc. | 1.3 Million USD | -48.118% |
| Viatris Inc. | 15.42 Billion USD | 99.987% |
| Rockwell Medical, Inc. | 83.61 Million USD | 97.694% |
| Aytu BioPharma, Inc. | 81 Million USD | 97.619% |
| Tilray Brands, Inc. | 788.94 Million USD | 99.756% |
| PetIQ, Inc. | 1.1 Billion USD | 99.825% |
| Talphera, Inc. | 651 Thousand USD | -196.236% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 99.898% |
| Alimera Sciences, Inc. | 80.75 Million USD | 97.612% |
| Assertio Holdings, Inc. | 152.06 Million USD | 98.732% |
| Shuttle Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Avadel Pharmaceuticals plc | 27.96 Million USD | 93.103% |
| Hempacco Co., Inc. | 4.04 Million USD | 52.331% |
| Alvotech | 91.43 Million USD | 97.891% |
| Lantheus Holdings, Inc. | 1.29 Billion USD | 99.851% |
| Kamada Ltd. | 144.75 Million USD | 98.668% |
| Currenc Group, Inc. | 53.25 Million USD | 96.379% |
| Indivior PLC | 1.09 Billion USD | 99.824% |
| Evoke Pharma, Inc. | 5.18 Million USD | 62.775% |
| Flora Growth Corp. | 76.07 Million USD | 97.465% |
| Cyclo Therapeutics, Inc. | 1.07 Million USD | -79.161% |
| Evolus, Inc. | 202.08 Million USD | 99.046% |
| HUTCHMED (China) Limited | 837.99 Million USD | 99.77% |
| Amphastar Pharmaceuticals, Inc. | 644.39 Million USD | 99.701% |
| Akanda Corp. | 2.16 Million USD | 10.72% |